Synthesis and Application of a Novel Gene Delivery Vector for Non-Small-Cell Lung Cancer Therapy

Area of Science:

• Biomedical Engineering
• Oncology
• Gene Therapy

Background:

• Human Wnt inhibitory factor-1 (hWIF-1) is an anti-oncogene with therapeutic potential for non-small-cell lung cancer (NSCLC).
• Clinical application of hWIF-1 is hindered by its rapid elimination and degradation in vivo.
• Development of effective gene delivery vectors is crucial for hWIF-1 based NSCLC therapy.

Purpose of the Study:

• To synthesize and evaluate a novel polyethylenimine (PEI) derivative, PEI-SP5-2 (PES), for targeted delivery of hWIF-1 in NSCLC therapy.
• To assess the gene delivery capacity, particle characteristics, and anti-tumor efficacy of the PES/hWIF-1 complex.

Main Methods:

• Synthesis of a novel PEI derivative (PES) incorporating branched PEI1800 and an NSCLC-targeting peptide (SP5-2).
• Evaluation of PES gene delivery capacity and transfection efficiency in A549 cell lines.
• Characterization of PES/gene particle size and zeta potential.
• Assessment of PES/hWIF-1 complex efficacy in inhibiting tumor growth in vitro and in vivo.

Main Results:

• PES demonstrated excellent gene delivery capacity with a transfection efficiency of 50.02% ± 4.75% in A549 cells at a weight ratio of 100.
• PES/gene particles exhibited desirable characteristics: monodispersed with a hydrodynamic diameter of 47.55 nm and zeta potential of 24.9 mV.
• PES/hWIF-1 complexes significantly inhibited tumor growth in vitro and in vivo, indicating therapeutic potential.

Conclusions:

• PES is a promising novel gene delivery vector for NSCLC therapy.
• PES/hWIF-1 complexes effectively inhibit tumor growth, demonstrating potential for clinical application in non-small-cell lung cancer treatment.